Comprehensive genomic analyses have indicated that mutation profiles, including the frequencies of TP53 and CTNNB1 mutations, which act as major oncogenic drivers, rather than drug targets in HCC, vary among subtypes (49). The gene discussed is CTNNB1; the disease is hepatocellular carcinoma.